Cargando…
The Combination of Interferon-Alpha and Ponatinib Enables Faster and Deeper Molecular Responses in Patient with De Novo Blast Crisis of CML: Interferon-Alpha May Return as a CML Treatment
In the era of tyrosine kinase inhibitor (TKI) treatment, its effectiveness in treating chronic myelogenous leukemia (CML) has been improved, ensuring the same prognosis as that of healthy people of the same age. However, there are some patients with de novo blast crisis that undergoes acute conversi...
Autores principales: | Hayashi, Kunio, Ikegame, Kazuhiro, Takahashi, Naoto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8112961/ https://www.ncbi.nlm.nih.gov/pubmed/34055427 http://dx.doi.org/10.1155/2021/5518727 |
Ejemplares similares
-
S152: COMBINATORY THERAPY OF ASCIMINIB AND PONATINIB WAS EFFECTIVE IN THE TREATMENT OF BLAST PHASE CML CDX MODEL
por: Čuřík, Nikola, et al.
Publicado: (2023) -
Resistant mutations in CML and Ph(+)ALL – role of ponatinib
por: Miller, Geoffrey D, et al.
Publicado: (2014) -
Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
por: Zeng, Peng, et al.
Publicado: (2020) -
Extramedullary blast crisis of secondary CML accompanying marrow fibrosis
por: Go, Jai Hyang, et al.
Publicado: (2012) -
Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
por: Matsuda, Yasufumi, et al.
Publicado: (2016)